NCT00432666 - IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

November 30, 2006

Study Completion Date

May 31, 2008

Conditions

Post-stroke Upper Limb Spasticity

Interventions

DRUG

IncobotulinumtoxinA (Xeomin)

"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"

DRUG

Placebo

Trial Locations (3)

Unknown

Czech Republic

Hungary

Poland